Financial Position - Cash and investments as of March 31, 2025, were $9.8 million, adjusted to include proceeds from the first tranche of private placement financing[1] - Cash and cash equivalents were $5.4 million as of March 31, 2025, down from $8.9 million at the end of 2024[19] - Total liabilities as of March 31, 2025, were $9.4 million, compared to $10.2 million at the end of 2024[19] Clinical Development - The company activated three new clinical study sites in 2025, with five additional sites expected by mid-year, totaling 13 sites[2] - The FDA approved a reduction in the NEPHRO CRRT clinical study from 166 patients to 70, with a primary endpoint powered at 90%[3] Financing Activities - Talphera secured financing of up to $14.8 million, with the first tranche of $4.4 million closing on April 2, 2025[4] Operating Expenses - Cash operating expenses for 2025 are expected to be between $17 million and $19 million, including costs for the NEPHRO CRRT trial[6] - Combined R&D and SG&A expenses for Q1 2025 totaled $2.9 million, down from $4.2 million in Q1 2024[8] Net Loss - The net loss from continuing operations for Q1 2025 was $2.7 million, compared to a net loss of $4.0 million in Q1 2024[8] - Net loss attributable to common shareholders for Q1 2025 was $2.6 million, or $0.10 per share, compared to a net loss of $4.0 million, or $0.16 per share, in Q1 2024[8]
Talphera(TLPH) - 2025 Q1 - Quarterly Results